#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The Mediterranean diet ( MD ) has been recognized as a model of healthy eating because of its contribution to a healthy lifestyle and a better quality of life .
2-1	16-19	The	abstract[2]	new[2]	appos	2-5[0_2]
2-2	20-33	Mediterranean	abstract[2]	new[2]	_	_
2-3	34-38	diet	abstract[2]	new[2]	_	_
2-4	39-40	(	_	_	_	_
2-5	41-43	MD	abstract	giv	coref	3-1[11_0]
2-6	44-45	)	_	_	_	_
2-7	46-49	has	_	_	_	_
2-8	50-54	been	_	_	_	_
2-9	55-65	recognized	_	_	_	_
2-10	66-68	as	_	_	_	_
2-11	69-70	a	abstract[4]	new[4]	ana	2-18[0_4]
2-12	71-76	model	abstract[4]	new[4]	_	_
2-13	77-79	of	abstract[4]	new[4]	_	_
2-14	80-87	healthy	abstract[4]|event[5]	new[4]|new[5]	_	_
2-15	88-94	eating	abstract[4]|event[5]	new[4]|new[5]	_	_
2-16	95-102	because	_	_	_	_
2-17	103-105	of	_	_	_	_
2-18	106-109	its	abstract|abstract[7]	giv|new[7]	_	_
2-19	110-122	contribution	abstract[7]	new[7]	_	_
2-20	123-125	to	abstract[7]	new[7]	_	_
2-21	126-127	a	abstract[7]|abstract[8]	new[7]|new[8]	coref	4-39[21_8]
2-22	128-135	healthy	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-23	136-145	lifestyle	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-24	146-149	and	abstract[7]	new[7]	_	_
2-25	150-151	a	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-26	152-158	better	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-27	159-166	quality	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-28	167-169	of	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-29	170-174	life	abstract[7]|abstract[9]|abstract	new[7]|new[9]|new	coref	4-14
2-30	175-176	.	_	_	_	_

#Text=The MD is much more than a dietary pattern .
3-1	177-180	The	abstract[11]	giv[11]	coref	4-1[14_11]
3-2	181-183	MD	abstract[11]	giv[11]	_	_
3-3	184-186	is	_	_	_	_
3-4	187-191	much	_	_	_	_
3-5	192-196	more	_	_	_	_
3-6	197-201	than	_	_	_	_
3-7	202-203	a	abstract[12]	new[12]	_	_
3-8	204-211	dietary	abstract[12]	new[12]	_	_
3-9	212-219	pattern	abstract[12]	new[12]	_	_
3-10	220-221	.	_	_	_	_

#Text=The word diet comes from the Greek diaita and means ‘ way of life ’ and the MD holds true to this meaning as MD covers not only what to eat but how to eat and live ( active lifestyle , prioritizing culinary activities , etc. ) .
4-1	222-225	The	abstract[13]|abstract[14]	new[13]|giv[14]	coref	4-17[18_14]
4-2	226-230	word	abstract[13]|abstract[14]	new[13]|giv[14]	_	_
4-3	231-235	diet	abstract[14]	giv[14]	_	_
4-4	236-241	comes	_	_	_	_
4-5	242-246	from	_	_	_	_
4-6	247-250	the	abstract[15]	new[15]	_	_
4-7	251-256	Greek	abstract[15]	new[15]	_	_
4-8	257-263	diaita	abstract[15]	new[15]	_	_
4-9	264-267	and	_	_	_	_
4-10	268-273	means	abstract	new	coref|none	4-22[19_0]|4-10[0_19]
4-11	274-275	‘	_	_	_	_
4-12	276-279	way	abstract[16]	new[16]	_	_
4-13	280-282	of	abstract[16]	new[16]	_	_
4-14	283-287	life	abstract[16]|abstract	new[16]|giv	_	_
4-15	288-289	’	_	_	_	_
4-16	290-293	and	_	_	_	_
4-17	294-297	the	abstract[18]	giv[18]	coref	4-25[0_18]
4-18	298-300	MD	abstract[18]	giv[18]	_	_
4-19	301-306	holds	_	_	_	_
4-20	307-311	true	_	_	_	_
4-21	312-314	to	_	_	_	_
4-22	315-319	this	abstract[19]	new[19]	_	_
4-23	320-327	meaning	abstract[19]	new[19]	_	_
4-24	328-330	as	_	_	_	_
4-25	331-333	MD	abstract	giv	coref	6-4[30_0]
4-26	334-340	covers	_	_	_	_
4-27	341-344	not	_	_	_	_
4-28	345-349	only	_	_	_	_
4-29	350-354	what	_	_	_	_
4-30	355-357	to	_	_	_	_
4-31	358-361	eat	_	_	_	_
4-32	362-365	but	_	_	_	_
4-33	366-369	how	_	_	_	_
4-34	370-372	to	_	_	_	_
4-35	373-376	eat	_	_	_	_
4-36	377-380	and	_	_	_	_
4-37	381-385	live	_	_	_	_
4-38	386-387	(	_	_	_	_
4-39	388-394	active	abstract[21]	giv[21]	ana	5-2[0_21]
4-40	395-404	lifestyle	abstract[21]	giv[21]	_	_
4-41	405-406	,	_	_	_	_
4-42	407-419	prioritizing	_	_	_	_
4-43	420-428	culinary	event[22]	new[22]	_	_
4-44	429-439	activities	event[22]	new[22]	_	_
4-45	440-441	,	_	_	_	_
4-46	442-446	etc.	_	_	_	_
4-47	447-448	)	_	_	_	_
4-48	449-450	.	_	_	_	_

#Text=And it should be preserved in the Mediterranean basin where , in the past decades , dietary trends are departing from traditional dietary patterns .
5-1	451-454	And	_	_	_	_
5-2	455-457	it	abstract	giv	_	_
5-3	458-464	should	_	_	_	_
5-4	465-467	be	_	_	_	_
5-5	468-477	preserved	_	_	_	_
5-6	478-480	in	_	_	_	_
5-7	481-484	the	place[24]	new[24]	_	_
5-8	485-498	Mediterranean	place[24]	new[24]	_	_
5-9	499-504	basin	place[24]	new[24]	_	_
5-10	505-510	where	place[24]	new[24]	_	_
5-11	511-512	,	place[24]	new[24]	_	_
5-12	513-515	in	place[24]	new[24]	_	_
5-13	516-519	the	place[24]|time[25]	new[24]|new[25]	coref	7-17[81_25]
5-14	520-524	past	place[24]|time[25]	new[24]|new[25]	_	_
5-15	525-532	decades	place[24]|time[25]	new[24]|new[25]	_	_
5-16	533-534	,	place[24]	new[24]	_	_
5-17	535-542	dietary	place[24]|abstract[26]	new[24]|new[26]	coref	7-14[80_26]
5-18	543-549	trends	place[24]|abstract[26]	new[24]|new[26]	_	_
5-19	550-553	are	place[24]	new[24]	_	_
5-20	554-563	departing	place[24]	new[24]	_	_
5-21	564-568	from	place[24]	new[24]	_	_
5-22	569-580	traditional	place[24]|abstract[28]	new[24]|new[28]	_	_
5-23	581-588	dietary	place[24]|substance|abstract[28]	new[24]|new|new[28]	_	_
5-24	589-597	patterns	place[24]|abstract[28]	new[24]|new[28]	_	_
5-25	598-599	.	_	_	_	_

#Text=The principles underlying the MD — widely documented elsewhere — can be summarized as follows : high consumption of fruits , vegetables , cereals ( especially whole seeds ) , legumes , and nuts ; relatively high fat consumption ( up to 40 % of total energy intake ) , mainly monounsaturated fatty acids ( MUFAs ) from extra-virgin olive oil , the main fat used for seasoning and cooking ; moderate to high consumption of fish ; moderate dairy product consumption , usually in the form of yogurt and cheese ; low red meat and meat product consumption ; moderate alcohol consumption , mainly in the form of red wine during meals ; low consumption of simple sugars ( pastries , soft drinks , etc. ) ; and high consumption of herbs and spices — an important source of micronutrients , including calcium ( Ca ) — used to flavor dishes .
6-1	600-603	The	abstract[29]	new[29]	_	_
6-2	604-614	principles	abstract[29]	new[29]	_	_
6-3	615-625	underlying	abstract[29]	new[29]	_	_
6-4	626-629	the	abstract[29]|abstract[30]	new[29]|giv[30]	coref	7-1[78_30]
6-5	630-632	MD	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
6-6	633-634	—	abstract[29]	new[29]	_	_
6-7	635-641	widely	abstract[29]	new[29]	_	_
6-8	642-652	documented	abstract[29]	new[29]	_	_
6-9	653-662	elsewhere	abstract[29]	new[29]	_	_
6-10	663-664	—	_	_	_	_
6-11	665-668	can	_	_	_	_
6-12	669-671	be	_	_	_	_
6-13	672-682	summarized	_	_	_	_
6-14	683-685	as	_	_	_	_
6-15	686-693	follows	_	_	_	_
6-16	694-695	:	_	_	_	_
6-17	696-700	high	abstract[31]	new[31]	coref	6-36[39_31]
6-18	701-712	consumption	abstract[31]	new[31]	_	_
6-19	713-715	of	abstract[31]	new[31]	_	_
6-20	716-722	fruits	abstract[31]|substance	new[31]|new	_	_
6-21	723-724	,	abstract[31]	new[31]	_	_
6-22	725-735	vegetables	abstract[31]|plant	new[31]|new	_	_
6-23	736-737	,	abstract[31]	new[31]	_	_
6-24	738-745	cereals	abstract[31]|substance	new[31]|new	_	_
6-25	746-747	(	abstract[31]	new[31]	_	_
6-26	748-758	especially	abstract[31]|plant[35]	new[31]|new[35]	_	_
6-27	759-764	whole	abstract[31]|plant[35]	new[31]|new[35]	_	_
6-28	765-770	seeds	abstract[31]|plant[35]	new[31]|new[35]	_	_
6-29	771-772	)	abstract[31]	new[31]	_	_
6-30	773-774	,	abstract[31]	new[31]	_	_
6-31	775-782	legumes	abstract[31]|substance	new[31]|new	_	_
6-32	783-784	,	abstract[31]	new[31]	_	_
6-33	785-788	and	abstract[31]	new[31]	_	_
6-34	789-793	nuts	abstract[31]|substance	new[31]|new	_	_
6-35	794-795	;	abstract[31]	new[31]	_	_
6-36	796-806	relatively	abstract[31]|abstract[39]	new[31]|giv[39]	coref	6-79[53_39]
6-37	807-811	high	abstract[31]|abstract[39]	new[31]|giv[39]	_	_
6-38	812-815	fat	abstract[31]|substance|abstract[39]	new[31]|new|giv[39]	_	_
6-39	816-827	consumption	abstract[31]|abstract[39]	new[31]|giv[39]	_	_
6-40	828-829	(	abstract[31]	new[31]	_	_
6-41	830-832	up	abstract[31]|abstract[40]	new[31]|new[40]	_	_
6-42	833-835	to	abstract[31]|abstract[40]	new[31]|new[40]	_	_
6-43	836-838	40	abstract[31]|abstract[40]	new[31]|new[40]	_	_
6-44	839-840	%	abstract[31]|abstract[40]	new[31]|new[40]	_	_
6-45	841-843	of	abstract[31]|abstract[40]	new[31]|new[40]	_	_
6-46	844-849	total	abstract[31]|abstract[40]|event[42]	new[31]|new[40]|new[42]	_	_
6-47	850-856	energy	abstract[31]|abstract[40]|substance|event[42]	new[31]|new[40]|new|new[42]	_	_
6-48	857-863	intake	abstract[31]|abstract[40]|event[42]	new[31]|new[40]|new[42]	_	_
6-49	864-865	)	abstract[31]	new[31]	_	_
6-50	866-867	,	abstract[31]	new[31]	_	_
6-51	868-874	mainly	abstract[31]|substance[44]	new[31]|new[44]	_	_
6-52	875-890	monounsaturated	abstract[31]|substance[44]	new[31]|new[44]	_	_
6-53	891-896	fatty	abstract[31]|abstract|substance[44]	new[31]|new|new[44]	_	_
6-54	897-902	acids	abstract[31]|substance[44]	new[31]|new[44]	_	_
6-55	903-904	(	abstract[31]	new[31]	_	_
6-56	905-910	MUFAs	abstract[31]|substance	new[31]|new	_	_
6-57	911-912	)	abstract[31]	new[31]	_	_
6-58	913-917	from	abstract[31]	new[31]	_	_
6-59	918-930	extra-virgin	abstract[31]|substance[46]	new[31]|new[46]	appos	6-63[47_46]
6-60	931-936	olive	abstract[31]|substance[46]	new[31]|new[46]	_	_
6-61	937-940	oil	abstract[31]|substance[46]	new[31]|new[46]	_	_
6-62	941-942	,	abstract[31]	new[31]	_	_
6-63	943-946	the	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-64	947-951	main	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-65	952-955	fat	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-66	956-960	used	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-67	961-964	for	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-68	965-974	seasoning	abstract[31]|substance[47]|substance	new[31]|giv[47]|new	_	_
6-69	975-978	and	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-70	979-986	cooking	abstract[31]|substance[47]	new[31]|giv[47]	_	_
6-71	987-988	;	abstract[31]	new[31]	_	_
6-72	989-997	moderate	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	coref|coref	6-72[57_49]|6-97[0_57]
6-73	998-1000	to	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	_	_
6-74	1001-1005	high	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	_	_
6-75	1006-1017	consumption	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	_	_
6-76	1018-1020	of	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	_	_
6-77	1021-1025	fish	abstract[31]|substance[49]|animal|substance[57]	new[31]|new[49]|new|giv[57]	_	_
6-78	1026-1027	;	abstract[31]|substance[49]|substance[57]	new[31]|new[49]|giv[57]	_	_
6-79	1028-1036	moderate	abstract[31]|substance[49]|abstract[53]|substance[57]	new[31]|new[49]|giv[53]|giv[57]	coref	6-97[60_53]
6-80	1037-1042	dairy	abstract[31]|substance[49]|person|substance[52]|abstract[53]|substance[57]	new[31]|new[49]|new|new[52]|giv[53]|giv[57]	coref	6-97[59_52]
6-81	1043-1050	product	abstract[31]|substance[49]|substance[52]|abstract[53]|substance[57]	new[31]|new[49]|new[52]|giv[53]|giv[57]	_	_
6-82	1051-1062	consumption	abstract[31]|substance[49]|abstract[53]|substance[57]	new[31]|new[49]|giv[53]|giv[57]	_	_
6-83	1063-1064	,	abstract[31]|substance[49]|abstract[53]|substance[57]	new[31]|new[49]|giv[53]|giv[57]	_	_
6-84	1065-1072	usually	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-85	1073-1075	in	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-86	1076-1079	the	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-87	1080-1084	form	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-88	1085-1087	of	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-89	1088-1094	yogurt	abstract[31]|substance[49]|abstract[53]|abstract[54]|object|substance[57]	new[31]|new[49]|giv[53]|new[54]|new|giv[57]	_	_
6-90	1095-1098	and	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-91	1099-1105	cheese	abstract[31]|substance[49]|abstract[53]|abstract[54]|object|substance[57]	new[31]|new[49]|giv[53]|new[54]|new|giv[57]	_	_
6-92	1106-1107	;	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-93	1108-1111	low	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-94	1112-1115	red	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-95	1116-1120	meat	abstract[31]|substance[49]|abstract[53]|abstract[54]|substance[57]	new[31]|new[49]|giv[53]|new[54]|giv[57]	_	_
6-96	1121-1124	and	abstract[31]|abstract[53]|abstract[54]	new[31]|giv[53]|new[54]	_	_
6-97	1125-1129	meat	abstract[31]|abstract[53]|abstract[54]|substance|substance[59]|abstract[60]	new[31]|giv[53]|new[54]|giv|giv[59]|giv[60]	coref	6-101[62_60]
6-98	1130-1137	product	abstract[31]|abstract[53]|abstract[54]|substance[59]|abstract[60]	new[31]|giv[53]|new[54]|giv[59]|giv[60]	_	_
6-99	1138-1149	consumption	abstract[31]|abstract[53]|abstract[54]|abstract[60]	new[31]|giv[53]|new[54]|giv[60]	_	_
6-100	1150-1151	;	abstract[31]	new[31]	_	_
6-101	1152-1160	moderate	abstract[31]|abstract[62]	new[31]|giv[62]	_	_
6-102	1161-1168	alcohol	abstract[31]|substance|abstract[62]	new[31]|new|giv[62]	_	_
6-103	1169-1180	consumption	abstract[31]|abstract[62]	new[31]|giv[62]	_	_
6-104	1181-1182	,	abstract[31]|abstract[62]	new[31]|giv[62]	_	_
6-105	1183-1189	mainly	abstract[31]|abstract[62]|abstract[63]	new[31]|giv[62]|new[63]	_	_
6-106	1190-1192	in	abstract[31]|abstract[62]|abstract[63]	new[31]|giv[62]|new[63]	_	_
6-107	1193-1196	the	abstract[31]|abstract[62]|abstract[63]	new[31]|giv[62]|new[63]	_	_
6-108	1197-1201	form	abstract[31]|abstract[62]|abstract[63]	new[31]|giv[62]|new[63]	_	_
6-109	1202-1204	of	abstract[31]|abstract[62]|abstract[63]	new[31]|giv[62]|new[63]	_	_
6-110	1205-1208	red	abstract[31]|abstract[62]|abstract[63]|substance[64]	new[31]|giv[62]|new[63]|new[64]	_	_
6-111	1209-1213	wine	abstract[31]|abstract[62]|abstract[63]|substance[64]	new[31]|giv[62]|new[63]|new[64]	_	_
6-112	1214-1220	during	abstract[31]|abstract[62]	new[31]|giv[62]	_	_
6-113	1221-1226	meals	abstract[31]|abstract[62]|object	new[31]|giv[62]|new	_	_
6-114	1227-1228	;	abstract[31]	new[31]	_	_
6-115	1229-1232	low	abstract[31]|event[66]	new[31]|new[66]	_	_
6-116	1233-1244	consumption	abstract[31]|event[66]	new[31]|new[66]	_	_
6-117	1245-1247	of	abstract[31]|event[66]	new[31]|new[66]	_	_
6-118	1248-1254	simple	abstract[31]|event[66]|substance[67]	new[31]|new[66]|new[67]	_	_
6-119	1255-1261	sugars	abstract[31]|event[66]|substance[67]	new[31]|new[66]|new[67]	_	_
6-120	1262-1263	(	abstract[31]	new[31]	_	_
6-121	1264-1272	pastries	abstract[31]|abstract	new[31]|new	_	_
6-122	1273-1274	,	abstract[31]	new[31]	_	_
6-123	1275-1279	soft	abstract[31]|substance[69]	new[31]|new[69]	_	_
6-124	1280-1286	drinks	abstract[31]|substance[69]	new[31]|new[69]	_	_
6-125	1287-1288	,	abstract[31]	new[31]	_	_
6-126	1289-1293	etc.	abstract[31]	new[31]	_	_
6-127	1294-1295	)	abstract[31]	new[31]	_	_
6-128	1296-1297	;	abstract[31]	new[31]	_	_
6-129	1298-1301	and	abstract[31]	new[31]	_	_
6-130	1302-1306	high	abstract[31]|event[70]	new[31]|new[70]	_	_
6-131	1307-1318	consumption	abstract[31]|event[70]	new[31]|new[70]	_	_
6-132	1319-1321	of	abstract[31]|event[70]	new[31]|new[70]	_	_
6-133	1322-1327	herbs	abstract[31]|event[70]|plant	new[31]|new[70]|new	_	_
6-134	1328-1331	and	abstract[31]|event[70]	new[31]|new[70]	_	_
6-135	1332-1338	spices	abstract[31]|event[70]|object	new[31]|new[70]|new	_	_
6-136	1339-1340	—	_	_	_	_
6-137	1341-1343	an	substance[73]	new[73]	_	_
6-138	1344-1353	important	substance[73]	new[73]	_	_
6-139	1354-1360	source	substance[73]	new[73]	_	_
6-140	1361-1363	of	substance[73]	new[73]	_	_
6-141	1364-1378	micronutrients	substance[73]|substance[74]	new[73]|new[74]	_	_
6-142	1379-1380	,	substance[73]|substance[74]	new[73]|new[74]	_	_
6-143	1381-1390	including	substance[73]|substance[74]	new[73]|new[74]	_	_
6-144	1391-1398	calcium	substance[73]|substance[74]|substance	new[73]|new[74]|new	appos	6-146
6-145	1399-1400	(	_	_	_	_
6-146	1401-1403	Ca	substance	giv	_	_
6-147	1404-1405	)	_	_	_	_
6-148	1406-1407	—	_	_	_	_
6-149	1408-1412	used	_	_	_	_
6-150	1413-1415	to	_	_	_	_
6-151	1416-1422	flavor	_	_	_	_
6-152	1423-1429	dishes	object	new	_	_
6-153	1430-1431	.	_	_	_	_

#Text=This traditional diet , however , has been affected by the onslaught of dietary trends of recent decades .
7-1	1432-1436	This	abstract[78]	giv[78]	coref	18-1[179_78]
7-2	1437-1448	traditional	abstract[78]	giv[78]	_	_
7-3	1449-1453	diet	abstract[78]	giv[78]	_	_
7-4	1454-1455	,	_	_	_	_
7-5	1456-1463	however	_	_	_	_
7-6	1464-1465	,	_	_	_	_
7-7	1466-1469	has	_	_	_	_
7-8	1470-1474	been	_	_	_	_
7-9	1475-1483	affected	_	_	_	_
7-10	1484-1486	by	_	_	_	_
7-11	1487-1490	the	event[79]	new[79]	_	_
7-12	1491-1500	onslaught	event[79]	new[79]	_	_
7-13	1501-1503	of	event[79]	new[79]	_	_
7-14	1504-1511	dietary	event[79]|abstract[80]	new[79]|giv[80]	_	_
7-15	1512-1518	trends	event[79]|abstract[80]	new[79]|giv[80]	_	_
7-16	1519-1521	of	event[79]|abstract[80]	new[79]|giv[80]	_	_
7-17	1522-1528	recent	event[79]|abstract[80]|time[81]	new[79]|giv[80]|giv[81]	_	_
7-18	1529-1536	decades	event[79]|abstract[80]|time[81]	new[79]|giv[80]|giv[81]	_	_
7-19	1537-1538	.	_	_	_	_

#Text=Osteoporosis ( OP ) is among the diseases with the highest incidence in advanced age , i.e. , coronary heart diseases , cancer , respiratory system diseases , depression , and neurodegenerative diseases such as Alzheimer ’s disease .
8-1	1539-1551	Osteoporosis	abstract	new	appos	8-3
8-2	1552-1553	(	_	_	_	_
8-3	1554-1556	OP	abstract	giv	coref	8-36[96_0]
8-4	1557-1558	)	_	_	_	_
8-5	1559-1561	is	_	_	_	_
8-6	1562-1567	among	_	_	_	_
8-7	1568-1571	the	abstract[84]	new[84]	appos	8-17[88_84]
8-8	1572-1580	diseases	abstract[84]	new[84]	_	_
8-9	1581-1585	with	abstract[84]	new[84]	_	_
8-10	1586-1589	the	abstract[84]|abstract[85]	new[84]|new[85]	coref	12-32[137_85]
8-11	1590-1597	highest	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-12	1598-1607	incidence	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-13	1608-1610	in	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-14	1611-1619	advanced	abstract[84]|abstract[85]|abstract[86]	new[84]|new[85]|new[86]	_	_
8-15	1620-1623	age	abstract[84]|abstract[85]|abstract[86]	new[84]|new[85]|new[86]	_	_
8-16	1624-1625	,	_	_	_	_
8-17	1626-1630	i.e.	abstract[88]|abstract[89]	giv[88]|giv[89]	appos|appos	8-17[89_88]|8-23[0_89]
8-18	1631-1632	,	abstract[88]|abstract[89]	giv[88]|giv[89]	_	_
8-19	1633-1641	coronary	abstract[88]|abstract[89]	giv[88]|giv[89]	_	_
8-20	1642-1647	heart	object|abstract[88]|abstract[89]	new|giv[88]|giv[89]	_	_
8-21	1648-1656	diseases	abstract[88]|abstract[89]	giv[88]|giv[89]	_	_
8-22	1657-1658	,	abstract[89]	giv[89]	_	_
8-23	1659-1665	cancer	abstract[89]|abstract	giv[89]|giv	appos	8-25[92_0]
8-24	1666-1667	,	abstract[89]	giv[89]	_	_
8-25	1668-1679	respiratory	abstract[89]|object[91]|abstract[92]	giv[89]|new[91]|giv[92]	appos	8-29[0_92]
8-26	1680-1686	system	abstract[89]|object[91]|abstract[92]	giv[89]|new[91]|giv[92]	_	_
8-27	1687-1695	diseases	abstract[89]|abstract[92]	giv[89]|giv[92]	_	_
8-28	1696-1697	,	abstract[89]	giv[89]	_	_
8-29	1698-1708	depression	abstract[89]|abstract	giv[89]|giv	appos	8-32[94_0]
8-30	1709-1710	,	abstract[89]	giv[89]	_	_
8-31	1711-1714	and	abstract[89]	giv[89]	_	_
8-32	1715-1732	neurodegenerative	abstract[89]|abstract[94]	giv[89]|giv[94]	coref	16-23[173_94]
8-33	1733-1741	diseases	abstract[89]|abstract[94]	giv[89]|giv[94]	_	_
8-34	1742-1746	such	abstract[89]|abstract[94]	giv[89]|giv[94]	_	_
8-35	1747-1749	as	abstract[89]|abstract[94]	giv[89]|giv[94]	_	_
8-36	1750-1759	Alzheimer	abstract[89]|abstract[94]|abstract[95]|abstract[96]	giv[89]|giv[94]|new[95]|giv[96]	coref	9-3[0_96]
8-37	1760-1762	’s	abstract[89]|abstract[94]|abstract[95]|abstract[96]	giv[89]|giv[94]|new[95]|giv[96]	_	_
8-38	1763-1770	disease	abstract[89]|abstract[94]|abstract[96]	giv[89]|giv[94]|giv[96]	_	_
8-39	1771-1772	.	_	_	_	_

#Text=Associated with OP , especially prevalent among older women , is bone fracture risk .
9-1	1773-1783	Associated	abstract[101]	new[101]	coref	11-32[126_101]
9-2	1784-1788	with	abstract[101]	new[101]	_	_
9-3	1789-1791	OP	abstract|abstract[101]	giv|new[101]	coref	11-1
9-4	1792-1793	,	abstract[101]	new[101]	_	_
9-5	1794-1804	especially	abstract[101]	new[101]	_	_
9-6	1805-1814	prevalent	abstract[101]	new[101]	_	_
9-7	1815-1820	among	abstract[101]	new[101]	_	_
9-8	1821-1826	older	person[98]|abstract[101]	new[98]|new[101]	coref	13-16[146_98]
9-9	1827-1832	women	person[98]|abstract[101]	new[98]|new[101]	_	_
9-10	1833-1834	,	abstract[101]	new[101]	_	_
9-11	1835-1837	is	abstract[101]	new[101]	_	_
9-12	1838-1842	bone	object|event[100]|abstract[101]	new|new[100]|new[101]	coref|coref	10-19|14-10[154_100]
9-13	1843-1851	fracture	event[100]|abstract[101]	new[100]|new[101]	_	_
9-14	1852-1856	risk	abstract[101]	new[101]	_	_
9-15	1857-1858	.	_	_	_	_

#Text=This growing global health problem suggests that the prevention of OP and its complications and the maintenance of bone mass are public health concerns .
10-1	1859-1863	This	abstract[103]	new[103]	_	_
10-2	1864-1871	growing	abstract[103]	new[103]	_	_
10-3	1872-1878	global	abstract[103]	new[103]	_	_
10-4	1879-1885	health	abstract|abstract[103]	new|new[103]	coref	10-22[111_0]
10-5	1886-1893	problem	abstract[103]	new[103]	_	_
10-6	1894-1902	suggests	_	_	_	_
10-7	1903-1907	that	_	_	_	_
10-8	1908-1911	the	abstract[104]	new[104]	ana	10-13[0_104]
10-9	1912-1922	prevention	abstract[104]	new[104]	_	_
10-10	1923-1925	of	abstract[104]	new[104]	_	_
10-11	1926-1928	OP	abstract[104]|person	new[104]|new	coref	12-20
10-12	1929-1932	and	abstract[104]	new[104]	_	_
10-13	1933-1936	its	abstract[104]|abstract|abstract[107]	new[104]|giv|new[107]	coref	15-10[162_107]
10-14	1937-1950	complications	abstract[104]|abstract[107]	new[104]|new[107]	_	_
10-15	1951-1954	and	_	_	_	_
10-16	1955-1958	the	abstract[108]	new[108]	coref	10-22[112_108]
10-17	1959-1970	maintenance	abstract[108]	new[108]	_	_
10-18	1971-1973	of	abstract[108]	new[108]	_	_
10-19	1974-1978	bone	abstract[108]|object|abstract[110]	new[108]|giv|new[110]	coref|coref	11-10|11-10[116_110]
10-20	1979-1983	mass	abstract[108]|abstract[110]	new[108]|new[110]	_	_
10-21	1984-1987	are	_	_	_	_
10-22	1988-1994	public	abstract[111]|abstract[112]	giv[111]|giv[112]	coref	19-15[187_111]
10-23	1995-2001	health	abstract[111]|abstract[112]	giv[111]|giv[112]	_	_
10-24	2002-2010	concerns	abstract[112]	giv[112]	_	_
10-25	2011-2012	.	_	_	_	_

#Text=OP is a systemic disease characterized by a low bone mass index and destruction of the microarchitecture of bone mass — i.e. , bone mineral density ( BMD ) — posing a major risk of fractures .
11-1	2013-2015	OP	abstract	giv	coref	11-3[114_0]
11-2	2016-2018	is	_	_	_	_
11-3	2019-2020	a	abstract[114]	giv[114]	coref	12-26[136_114]
11-4	2021-2029	systemic	abstract[114]	giv[114]	_	_
11-5	2030-2037	disease	abstract[114]	giv[114]	_	_
11-6	2038-2051	characterized	abstract[114]	giv[114]	_	_
11-7	2052-2054	by	abstract[114]	giv[114]	_	_
11-8	2055-2056	a	abstract[114]|abstract[117]	giv[114]|new[117]	_	_
11-9	2057-2060	low	abstract[114]|abstract[117]	giv[114]|new[117]	_	_
11-10	2061-2065	bone	abstract[114]|object|abstract[116]|abstract[117]	giv[114]|giv|giv[116]|new[117]	coref|coref	11-19|11-19[121_116]
11-11	2066-2070	mass	abstract[114]|abstract[116]|abstract[117]	giv[114]|giv[116]|new[117]	_	_
11-12	2071-2076	index	abstract[114]|abstract[117]	giv[114]|new[117]	_	_
11-13	2077-2080	and	abstract[114]	giv[114]	_	_
11-14	2081-2092	destruction	abstract[114]|event[118]	giv[114]|new[118]	_	_
11-15	2093-2095	of	abstract[114]|event[118]	giv[114]|new[118]	_	_
11-16	2096-2099	the	abstract[114]|event[118]|abstract[119]	giv[114]|new[118]|new[119]	_	_
11-17	2100-2117	microarchitecture	abstract[114]|event[118]|abstract[119]	giv[114]|new[118]|new[119]	_	_
11-18	2118-2120	of	abstract[114]|event[118]|abstract[119]	giv[114]|new[118]|new[119]	_	_
11-19	2121-2125	bone	abstract[114]|event[118]|abstract[119]|object|abstract[121]	giv[114]|new[118]|new[119]|giv|giv[121]	coref|coref	11-24|12-9[131_121]
11-20	2126-2130	mass	abstract[114]|event[118]|abstract[119]|abstract[121]	giv[114]|new[118]|new[119]|giv[121]	_	_
11-21	2131-2132	—	abstract[114]	giv[114]	_	_
11-22	2133-2137	i.e.	abstract[114]|abstract[124]	giv[114]|new[124]	appos	11-28[0_124]
11-23	2138-2139	,	abstract[114]|abstract[124]	giv[114]|new[124]	_	_
11-24	2140-2144	bone	abstract[114]|object|abstract[124]	giv[114]|giv|new[124]	coref	12-9
11-25	2145-2152	mineral	abstract[114]|substance|abstract[124]	giv[114]|new|new[124]	_	_
11-26	2153-2160	density	abstract[114]|abstract[124]	giv[114]|new[124]	_	_
11-27	2161-2162	(	abstract[114]	giv[114]	_	_
11-28	2163-2166	BMD	abstract[114]|abstract	giv[114]|giv	coref	18-17[182_0]
11-29	2167-2168	)	abstract[114]	giv[114]	_	_
11-30	2169-2170	—	abstract[114]	giv[114]	_	_
11-31	2171-2177	posing	abstract[114]	giv[114]	_	_
11-32	2178-2179	a	abstract[114]|abstract[126]	giv[114]|giv[126]	coref	16-15[171_126]
11-33	2180-2185	major	abstract[114]|abstract[126]	giv[114]|giv[126]	_	_
11-34	2186-2190	risk	abstract[114]|abstract[126]	giv[114]|giv[126]	_	_
11-35	2191-2193	of	abstract[114]|abstract[126]	giv[114]|giv[126]	_	_
11-36	2194-2203	fractures	abstract[114]|abstract[126]|event	giv[114]|giv[126]|new	coref	12-13
11-37	2204-2205	.	_	_	_	_

#Text=There are no symptoms indicating a reduction in bone mass , and fractures are the only clinical consequences of OP ; therefore , despite being the most common bone disease , the incidence is difficult to establish , and the prevalence is often based on estimates using indirect indicators such as fractures .
12-1	2206-2211	There	_	_	_	_
12-2	2212-2215	are	_	_	_	_
12-3	2216-2218	no	abstract[128]	new[128]	_	_
12-4	2219-2227	symptoms	abstract[128]	new[128]	_	_
12-5	2228-2238	indicating	abstract[128]	new[128]	_	_
12-6	2239-2240	a	abstract[128]|abstract[129]	new[128]|new[129]	coref	16-12[170_129]
12-7	2241-2250	reduction	abstract[128]|abstract[129]	new[128]|new[129]	_	_
12-8	2251-2253	in	abstract[128]|abstract[129]	new[128]|new[129]	_	_
12-9	2254-2258	bone	abstract[128]|abstract[129]|object|abstract[131]	new[128]|new[129]|giv|giv[131]	coref|coref	12-29|15-16[164_131]
12-10	2259-2263	mass	abstract[128]|abstract[129]|abstract[131]	new[128]|new[129]|giv[131]	_	_
12-11	2264-2265	,	_	_	_	_
12-12	2266-2269	and	_	_	_	_
12-13	2270-2279	fractures	event	giv	coref	12-15[133_0]
12-14	2280-2283	are	_	_	_	_
12-15	2284-2287	the	event[133]	giv[133]	coref	12-52[0_133]
12-16	2288-2292	only	event[133]	giv[133]	_	_
12-17	2293-2301	clinical	event[133]	giv[133]	_	_
12-18	2302-2314	consequences	event[133]	giv[133]	_	_
12-19	2315-2317	of	event[133]	giv[133]	_	_
12-20	2318-2320	OP	event[133]|person	giv[133]|giv	_	_
12-21	2321-2322	;	_	_	_	_
12-22	2323-2332	therefore	_	_	_	_
12-23	2333-2334	,	_	_	_	_
12-24	2335-2342	despite	_	_	_	_
12-25	2343-2348	being	_	_	_	_
12-26	2349-2352	the	abstract[136]	giv[136]	coref	15-7[159_136]
12-27	2353-2357	most	abstract[136]	giv[136]	_	_
12-28	2358-2364	common	abstract[136]	giv[136]	_	_
12-29	2365-2369	bone	object|abstract[136]	giv|giv[136]	coref	14-12
12-30	2370-2377	disease	abstract[136]	giv[136]	_	_
12-31	2378-2379	,	_	_	_	_
12-32	2380-2383	the	abstract[137]	giv[137]	_	_
12-33	2384-2393	incidence	abstract[137]	giv[137]	_	_
12-34	2394-2396	is	_	_	_	_
12-35	2397-2406	difficult	_	_	_	_
12-36	2407-2409	to	_	_	_	_
12-37	2410-2419	establish	_	_	_	_
12-38	2420-2421	,	_	_	_	_
12-39	2422-2425	and	_	_	_	_
12-40	2426-2429	the	abstract[138]	new[138]	coref	13-4[143_138]
12-41	2430-2440	prevalence	abstract[138]	new[138]	_	_
12-42	2441-2443	is	_	_	_	_
12-43	2444-2449	often	_	_	_	_
12-44	2450-2455	based	_	_	_	_
12-45	2456-2458	on	_	_	_	_
12-46	2459-2468	estimates	abstract[139]	new[139]	_	_
12-47	2469-2474	using	abstract[139]	new[139]	_	_
12-48	2475-2483	indirect	abstract[139]|abstract[140]	new[139]|new[140]	_	_
12-49	2484-2494	indicators	abstract[139]|abstract[140]	new[139]|new[140]	_	_
12-50	2495-2499	such	abstract[139]|abstract[140]	new[139]|new[140]	_	_
12-51	2500-2502	as	abstract[139]|abstract[140]	new[139]|new[140]	_	_
12-52	2503-2512	fractures	abstract[139]|abstract[140]|event	new[139]|new[140]|giv	coref	23-18[212_0]
12-53	2513-2514	.	_	_	_	_

#Text=In Spain , prevalence , as determined by densitometry , is about 30 % in women aged 50 years old , increasing to 50 % in women older than 70 years old .
13-1	2515-2517	In	_	_	_	_
13-2	2518-2523	Spain	place	new	_	_
13-3	2524-2525	,	_	_	_	_
13-4	2526-2536	prevalence	abstract[143]	giv[143]	coref	13-12[145_143]
13-5	2537-2538	,	abstract[143]	giv[143]	_	_
13-6	2539-2541	as	abstract[143]	giv[143]	_	_
13-7	2542-2552	determined	abstract[143]	giv[143]	_	_
13-8	2553-2555	by	abstract[143]	giv[143]	_	_
13-9	2556-2568	densitometry	abstract[143]|abstract	giv[143]|new	_	_
13-10	2569-2570	,	_	_	_	_
13-11	2571-2573	is	_	_	_	_
13-12	2574-2579	about	abstract[145]	giv[145]	coref	15-4[158_145]
13-13	2580-2582	30	abstract[145]	giv[145]	_	_
13-14	2583-2584	%	abstract[145]	giv[145]	_	_
13-15	2585-2587	in	abstract[145]	giv[145]	_	_
13-16	2588-2593	women	abstract[145]|person[146]	giv[145]|giv[146]	coref	13-27[149_146]
13-17	2594-2598	aged	abstract[145]|person[146]	giv[145]|giv[146]	_	_
13-18	2599-2601	50	abstract[145]|person[146]|time[147]	giv[145]|giv[146]|new[147]	_	_
13-19	2602-2607	years	abstract[145]|person[146]|time[147]	giv[145]|giv[146]|new[147]	_	_
13-20	2608-2611	old	abstract[145]|person[146]	giv[145]|giv[146]	_	_
13-21	2612-2613	,	abstract[145]	giv[145]	_	_
13-22	2614-2624	increasing	abstract[145]	giv[145]	_	_
13-23	2625-2627	to	abstract[145]	giv[145]	_	_
13-24	2628-2630	50	abstract[145]|abstract[148]	giv[145]|new[148]	_	_
13-25	2631-2632	%	abstract[145]|abstract[148]	giv[145]|new[148]	_	_
13-26	2633-2635	in	abstract[145]	giv[145]	_	_
13-27	2636-2641	women	abstract[145]|person[149]	giv[145]|giv[149]	coref	14-5[152_149]
13-28	2642-2647	older	abstract[145]|person[149]	giv[145]|giv[149]	_	_
13-29	2648-2652	than	_	_	_	_
13-30	2653-2655	70	time[150]	new[150]	_	_
13-31	2656-2661	years	time[150]	new[150]	_	_
13-32	2662-2665	old	_	_	_	_
13-33	2666-2667	.	_	_	_	_

#Text=About 40 % of Caucasian women will suffer at least one bone fracture after their 50s .
14-1	2668-2673	About	person[151]	new[151]	_	_
14-2	2674-2676	40	person[151]	new[151]	_	_
14-3	2677-2678	%	person[151]	new[151]	_	_
14-4	2679-2681	of	person[151]	new[151]	_	_
14-5	2682-2691	Caucasian	person[151]|person[152]	new[151]|giv[152]	ana	14-15[0_152]
14-6	2692-2697	women	person[151]|person[152]	new[151]|giv[152]	_	_
14-7	2698-2702	will	_	_	_	_
14-8	2703-2709	suffer	_	_	_	_
14-9	2710-2712	at	_	_	_	_
14-10	2713-2718	least	event[154]	giv[154]	coref	18-12[0_154]
14-11	2719-2722	one	event[154]	giv[154]	_	_
14-12	2723-2727	bone	object|event[154]	giv|giv[154]	coref	15-16
14-13	2728-2736	fracture	event[154]	giv[154]	_	_
14-14	2737-2742	after	_	_	_	_
14-15	2743-2748	their	person|time[156]	giv|new[156]	coref	19-18[188_0]
14-16	2749-2752	50s	time[156]	new[156]	_	_
14-17	2753-2754	.	_	_	_	_

#Text=Strategies to minimize the prevalence of the disease and its complications would be to enhance bone mass and reduce loss at advanced ages .
15-1	2755-2765	Strategies	abstract[157]	new[157]	_	_
15-2	2766-2768	to	abstract[157]	new[157]	_	_
15-3	2769-2777	minimize	abstract[157]	new[157]	_	_
15-4	2778-2781	the	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
15-5	2782-2792	prevalence	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
15-6	2793-2795	of	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
15-7	2796-2799	the	abstract[157]|abstract[158]|abstract[159]|abstract[160]	new[157]|giv[158]|giv[159]|giv[160]	coref|ana	15-7[160_159]|15-10[0_160]
15-8	2800-2807	disease	abstract[157]|abstract[158]|abstract[159]|abstract[160]	new[157]|giv[158]|giv[159]|giv[160]	_	_
15-9	2808-2811	and	abstract[157]|abstract[158]|abstract[160]	new[157]|giv[158]|giv[160]	_	_
15-10	2812-2815	its	abstract[157]|abstract[158]|abstract[160]|abstract|abstract[162]	new[157]|giv[158]|giv[160]|giv|giv[162]	_	_
15-11	2816-2829	complications	abstract[157]|abstract[158]|abstract[160]|abstract[162]	new[157]|giv[158]|giv[160]|giv[162]	_	_
15-12	2830-2835	would	_	_	_	_
15-13	2836-2838	be	_	_	_	_
15-14	2839-2841	to	_	_	_	_
15-15	2842-2849	enhance	_	_	_	_
15-16	2850-2854	bone	object|abstract[164]	giv|giv[164]	coref	19-15
15-17	2855-2859	mass	abstract[164]	giv[164]	_	_
15-18	2860-2863	and	_	_	_	_
15-19	2864-2870	reduce	_	_	_	_
15-20	2871-2875	loss	event	new	_	_
15-21	2876-2878	at	_	_	_	_
15-22	2879-2887	advanced	place[166]	new[166]	_	_
15-23	2888-2892	ages	place[166]	new[166]	_	_
15-24	2893-2894	.	_	_	_	_

#Text=There is convincing scientific evidence supporting the MD ’s role in the reduction of overall risk for diabetes , cardiovascular , and neurodegenerative diseases .
16-1	2895-2900	There	_	_	_	_
16-2	2901-2903	is	_	_	_	_
16-3	2904-2914	convincing	abstract[167]	new[167]	coref	17-10[176_167]
16-4	2915-2925	scientific	abstract[167]	new[167]	_	_
16-5	2926-2934	evidence	abstract[167]	new[167]	_	_
16-6	2935-2945	supporting	abstract[167]	new[167]	_	_
16-7	2946-2949	the	abstract[167]|abstract[169]	new[167]|new[169]	coref	19-8[184_169]
16-8	2950-2952	MD	abstract[167]|organization[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
16-9	2953-2955	’s	abstract[167]|organization[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
16-10	2956-2960	role	abstract[167]|abstract[169]	new[167]|new[169]	_	_
16-11	2961-2963	in	abstract[167]|abstract[169]	new[167]|new[169]	_	_
16-12	2964-2967	the	abstract[167]|abstract[169]|abstract[170]	new[167]|new[169]|giv[170]	coref	17-20[178_170]
16-13	2968-2977	reduction	abstract[167]|abstract[169]|abstract[170]	new[167]|new[169]|giv[170]	_	_
16-14	2978-2980	of	abstract[167]|abstract[169]|abstract[170]	new[167]|new[169]|giv[170]	_	_
16-15	2981-2988	overall	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-16	2989-2993	risk	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-17	2994-2997	for	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-18	2998-3006	diabetes	abstract[167]|abstract[169]|abstract[170]|abstract[171]|abstract	new[167]|new[169]|giv[170]|giv[171]|new	_	_
16-19	3007-3008	,	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-20	3009-3023	cardiovascular	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-21	3024-3025	,	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-22	3026-3029	and	abstract[167]|abstract[169]|abstract[170]|abstract[171]	new[167]|new[169]|giv[170]|giv[171]	_	_
16-23	3030-3047	neurodegenerative	abstract[167]|abstract[169]|abstract[170]|abstract[171]|abstract[173]	new[167]|new[169]|giv[170]|giv[171]|giv[173]	_	_
16-24	3048-3056	diseases	abstract[167]|abstract[169]|abstract[170]|abstract[171]|abstract[173]	new[167]|new[169]|giv[170]|giv[171]|giv[173]	_	_
16-25	3057-3058	.	_	_	_	_

#Text=Regarding site-specific cancers and inflammatory and metabolic conditions , the evidence is suggestive or weak and is unconvincing regarding low-density lipid reduction .
17-1	3059-3068	Regarding	_	_	_	_
17-2	3069-3082	site-specific	abstract[174]	new[174]	_	_
17-3	3083-3090	cancers	abstract[174]	new[174]	_	_
17-4	3091-3094	and	_	_	_	_
17-5	3095-3107	inflammatory	abstract[175]	new[175]	_	_
17-6	3108-3111	and	abstract[175]	new[175]	_	_
17-7	3112-3121	metabolic	abstract[175]	new[175]	_	_
17-8	3122-3132	conditions	abstract[175]	new[175]	_	_
17-9	3133-3134	,	_	_	_	_
17-10	3135-3138	the	abstract[176]	giv[176]	coref	19-3[183_176]
17-11	3139-3147	evidence	abstract[176]	giv[176]	_	_
17-12	3148-3150	is	_	_	_	_
17-13	3151-3161	suggestive	_	_	_	_
17-14	3162-3164	or	_	_	_	_
17-15	3165-3169	weak	_	_	_	_
17-16	3170-3173	and	_	_	_	_
17-17	3174-3176	is	_	_	_	_
17-18	3177-3189	unconvincing	_	_	_	_
17-19	3190-3199	regarding	_	_	_	_
17-20	3200-3211	low-density	substance[177]|abstract[178]	new[177]|giv[178]	_	_
17-21	3212-3217	lipid	substance[177]|abstract[178]	new[177]|giv[178]	_	_
17-22	3218-3227	reduction	abstract[178]	giv[178]	_	_
17-23	3228-3229	.	_	_	_	_

#Text=The MD has been shown to modestly reduce the risk of fracture and is associated with higher BMD .
18-1	3230-3233	The	abstract[179]	giv[179]	coref	19-11[185_179]
18-2	3234-3236	MD	abstract[179]	giv[179]	_	_
18-3	3237-3240	has	_	_	_	_
18-4	3241-3245	been	_	_	_	_
18-5	3246-3251	shown	_	_	_	_
18-6	3252-3254	to	_	_	_	_
18-7	3255-3263	modestly	_	_	_	_
18-8	3264-3270	reduce	_	_	_	_
18-9	3271-3274	the	abstract[180]	new[180]	coref	20-23[195_180]
18-10	3275-3279	risk	abstract[180]	new[180]	_	_
18-11	3280-3282	of	abstract[180]	new[180]	_	_
18-12	3283-3291	fracture	abstract[180]|event	new[180]|giv	coref	20-23
18-13	3292-3295	and	_	_	_	_
18-14	3296-3298	is	_	_	_	_
18-15	3299-3309	associated	_	_	_	_
18-16	3310-3314	with	_	_	_	_
18-17	3315-3321	higher	abstract[182]	giv[182]	_	_
18-18	3322-3325	BMD	abstract[182]	giv[182]	_	_
18-19	3326-3327	.	_	_	_	_

#Text=Thus , the overall evidence points toward the role of the MD in maintaining bone health , especially in postmenopausal women .
19-1	3328-3332	Thus	_	_	_	_
19-2	3333-3334	,	_	_	_	_
19-3	3335-3338	the	abstract[183]	giv[183]	_	_
19-4	3339-3346	overall	abstract[183]	giv[183]	_	_
19-5	3347-3355	evidence	abstract[183]	giv[183]	_	_
19-6	3356-3362	points	_	_	_	_
19-7	3363-3369	toward	_	_	_	_
19-8	3370-3373	the	abstract[184]	giv[184]	_	_
19-9	3374-3378	role	abstract[184]	giv[184]	_	_
19-10	3379-3381	of	abstract[184]	giv[184]	_	_
19-11	3382-3385	the	abstract[184]|abstract[185]	giv[184]|giv[185]	coref	20-21[0_185]
19-12	3386-3388	MD	abstract[184]|abstract[185]	giv[184]|giv[185]	_	_
19-13	3389-3391	in	_	_	_	_
19-14	3392-3403	maintaining	_	_	_	_
19-15	3404-3408	bone	object|abstract[187]	giv|giv[187]	coref	23-18
19-16	3409-3415	health	abstract[187]	giv[187]	_	_
19-17	3416-3417	,	_	_	_	_
19-18	3418-3428	especially	person[188]	giv[188]	_	_
19-19	3429-3431	in	person[188]	giv[188]	_	_
19-20	3432-3446	postmenopausal	person[188]	giv[188]	_	_
19-21	3447-3452	women	person[188]	giv[188]	_	_
19-22	3453-3454	.	_	_	_	_

#Text=Residual confounding factors in observational studies has become a major concern , with many international studies analyzing the relationship between diet and fracture risk .
20-1	3455-3463	Residual	abstract[189]	new[189]	coref	26-21[235_189]
20-2	3464-3475	confounding	abstract[189]	new[189]	_	_
20-3	3476-3483	factors	abstract[189]	new[189]	_	_
20-4	3484-3486	in	abstract[189]	new[189]	_	_
20-5	3487-3500	observational	abstract[189]|abstract[190]	new[189]|new[190]	coref	20-14[191_190]
20-6	3501-3508	studies	abstract[189]|abstract[190]	new[189]|new[190]	_	_
20-7	3509-3512	has	_	_	_	_
20-8	3513-3519	become	_	_	_	_
20-9	3520-3521	a	_	_	_	_
20-10	3522-3527	major	_	_	_	_
20-11	3528-3535	concern	_	_	_	_
20-12	3536-3537	,	_	_	_	_
20-13	3538-3542	with	_	_	_	_
20-14	3543-3547	many	abstract[191]	giv[191]	coref	21-15[199_191]
20-15	3548-3561	international	abstract[191]	giv[191]	_	_
20-16	3562-3569	studies	abstract[191]	giv[191]	_	_
20-17	3570-3579	analyzing	abstract[191]	giv[191]	_	_
20-18	3580-3583	the	abstract[191]|abstract[192]	giv[191]|new[192]	coref	26-8[229_192]
20-19	3584-3596	relationship	abstract[191]|abstract[192]	giv[191]|new[192]	_	_
20-20	3597-3604	between	abstract[191]|abstract[192]	giv[191]|new[192]	_	_
20-21	3605-3609	diet	abstract[191]|abstract[192]|abstract	giv[191]|new[192]|giv	coref	22-18[207_0]
20-22	3610-3613	and	abstract[191]|abstract[192]	giv[191]|new[192]	_	_
20-23	3614-3622	fracture	abstract[191]|abstract[192]|event|abstract[195]	giv[191]|new[192]|giv|giv[195]	coref	25-10
20-24	3623-3627	risk	abstract[191]|abstract[192]|abstract[195]	giv[191]|new[192]|giv[195]	_	_
20-25	3628-3629	.	_	_	_	_

#Text=For instance , bias should be taken into account when considering meta-analysis results on prospective cohort studies beyond the Mediterranean region .
21-1	3630-3633	For	_	_	_	_
21-2	3634-3642	instance	_	_	_	_
21-3	3643-3644	,	_	_	_	_
21-4	3645-3649	bias	abstract	new	_	_
21-5	3650-3656	should	_	_	_	_
21-6	3657-3659	be	_	_	_	_
21-7	3660-3665	taken	_	_	_	_
21-8	3666-3670	into	_	_	_	_
21-9	3671-3678	account	_	_	_	_
21-10	3679-3683	when	_	_	_	_
21-11	3684-3695	considering	_	_	_	_
21-12	3696-3709	meta-analysis	abstract[197]	new[197]	_	_
21-13	3710-3717	results	abstract[197]	new[197]	_	_
21-14	3718-3720	on	abstract[197]	new[197]	_	_
21-15	3721-3732	prospective	abstract[197]|abstract[199]	new[197]|giv[199]	coref	25-22[224_199]
21-16	3733-3739	cohort	abstract[197]|person|abstract[199]	new[197]|new|giv[199]	_	_
21-17	3740-3747	studies	abstract[197]|abstract[199]	new[197]|giv[199]	_	_
21-18	3748-3754	beyond	abstract[197]|abstract[199]	new[197]|giv[199]	_	_
21-19	3755-3758	the	abstract[197]|abstract[199]|place[200]	new[197]|giv[199]|new[200]	ana	22-1[0_200]
21-20	3759-3772	Mediterranean	abstract[197]|abstract[199]|place[200]	new[197]|giv[199]|new[200]	_	_
21-21	3773-3779	region	abstract[197]|abstract[199]|place[200]	new[197]|giv[199]|new[200]	_	_
21-22	3780-3781	.	_	_	_	_

#Text=This is due to the paucity of data and the lack of consensus on the definition of the MD .
22-1	3782-3786	This	place	giv	_	_
22-2	3787-3789	is	_	_	_	_
22-3	3790-3793	due	_	_	_	_
22-4	3794-3796	to	_	_	_	_
22-5	3797-3800	the	abstract[202]	new[202]	_	_
22-6	3801-3808	paucity	abstract[202]	new[202]	_	_
22-7	3809-3811	of	abstract[202]	new[202]	_	_
22-8	3812-3816	data	abstract[202]|abstract	new[202]|new	_	_
22-9	3817-3820	and	_	_	_	_
22-10	3821-3824	the	abstract[204]	new[204]	_	_
22-11	3825-3829	lack	abstract[204]	new[204]	_	_
22-12	3830-3832	of	abstract[204]	new[204]	_	_
22-13	3833-3842	consensus	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-14	3843-3845	on	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-15	3846-3849	the	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-16	3850-3860	definition	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-17	3861-3863	of	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-18	3864-3867	the	abstract[204]|abstract[205]|abstract[206]|abstract[207]	new[204]|new[205]|new[206]|giv[207]	coref	24-2[213_207]
22-19	3868-3870	MD	abstract[204]|abstract[205]|abstract[206]|abstract[207]	new[204]|new[205]|new[206]|giv[207]	_	_
22-20	3871-3872	.	_	_	_	_

#Text=Furthermore , physical activity has been demonstrated to be a robust indicator of a lower risk of bone fractures .
23-1	3873-3884	Furthermore	_	_	_	_
23-2	3885-3886	,	_	_	_	_
23-3	3887-3895	physical	abstract[208]	new[208]	coref	24-9[214_208]
23-4	3896-3904	activity	abstract[208]	new[208]	_	_
23-5	3905-3908	has	_	_	_	_
23-6	3909-3913	been	_	_	_	_
23-7	3914-3926	demonstrated	_	_	_	_
23-8	3927-3929	to	_	_	_	_
23-9	3930-3932	be	_	_	_	_
23-10	3933-3934	a	abstract[209]	new[209]	_	_
23-11	3935-3941	robust	abstract[209]	new[209]	_	_
23-12	3942-3951	indicator	abstract[209]	new[209]	_	_
23-13	3952-3954	of	abstract[209]	new[209]	_	_
23-14	3955-3956	a	abstract[209]|abstract[210]	new[209]|new[210]	coref	25-9[221_210]
23-15	3957-3962	lower	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-16	3963-3967	risk	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-17	3968-3970	of	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-18	3971-3975	bone	abstract[209]|abstract[210]|object|event[212]	new[209]|new[210]|giv|giv[212]	coref	25-9
23-19	3976-3985	fractures	abstract[209]|abstract[210]|event[212]	new[209]|new[210]|giv[212]	_	_
23-20	3986-3987	.	_	_	_	_

#Text=Since a healthier diet is related to higher physical activity levels , the latter needs also to be taken into account .
24-1	3988-3993	Since	_	_	_	_
24-2	3994-3995	a	abstract[213]	giv[213]	coref	26-11[230_213]
24-3	3996-4005	healthier	abstract[213]	giv[213]	_	_
24-4	4006-4010	diet	abstract[213]	giv[213]	_	_
24-5	4011-4013	is	_	_	_	_
24-6	4014-4021	related	_	_	_	_
24-7	4022-4024	to	_	_	_	_
24-8	4025-4031	higher	abstract[215]	new[215]	_	_
24-9	4032-4040	physical	abstract[214]|abstract[215]	giv[214]|new[215]	_	_
24-10	4041-4049	activity	abstract[214]|abstract[215]	giv[214]|new[215]	_	_
24-11	4050-4056	levels	abstract[215]	new[215]	_	_
24-12	4057-4058	,	_	_	_	_
24-13	4059-4062	the	abstract[216]	new[216]	_	_
24-14	4063-4069	latter	abstract[216]	new[216]	_	_
24-15	4070-4075	needs	_	_	_	_
24-16	4076-4080	also	_	_	_	_
24-17	4081-4083	to	_	_	_	_
24-18	4084-4086	be	_	_	_	_
24-19	4087-4092	taken	_	_	_	_
24-20	4093-4097	into	_	_	_	_
24-21	4098-4105	account	_	_	_	_
24-22	4106-4107	.	_	_	_	_

#Text=The observed inverse association between dietary quality and bone fracture risk should be interpreted with caution because the case-control design of most studies ’ findings cannot indicate causality .
25-1	4108-4111	The	abstract[217]	new[217]	_	_
25-2	4112-4120	observed	abstract[217]	new[217]	_	_
25-3	4121-4128	inverse	abstract[217]	new[217]	_	_
25-4	4129-4140	association	abstract[217]	new[217]	_	_
25-5	4141-4148	between	abstract[217]	new[217]	_	_
25-6	4149-4156	dietary	abstract[217]|abstract[218]	new[217]|new[218]	_	_
25-7	4157-4164	quality	abstract[217]|abstract[218]	new[217]|new[218]	_	_
25-8	4165-4168	and	abstract[217]	new[217]	_	_
25-9	4169-4173	bone	abstract[217]|object|abstract[221]	new[217]|giv|giv[221]	coref|coref	26-14|26-14[233_221]
25-10	4174-4182	fracture	abstract[217]|event|abstract[221]	new[217]|giv|giv[221]	coref	26-15
25-11	4183-4187	risk	abstract[217]|abstract[221]	new[217]|giv[221]	_	_
25-12	4188-4194	should	_	_	_	_
25-13	4195-4197	be	_	_	_	_
25-14	4198-4209	interpreted	_	_	_	_
25-15	4210-4214	with	_	_	_	_
25-16	4215-4222	caution	abstract	new	_	_
25-17	4223-4230	because	_	_	_	_
25-18	4231-4234	the	abstract[223]	new[223]	_	_
25-19	4235-4247	case-control	abstract[223]	new[223]	_	_
25-20	4248-4254	design	abstract[223]	new[223]	_	_
25-21	4255-4257	of	abstract[223]	new[223]	_	_
25-22	4258-4262	most	abstract[223]|abstract[224]|abstract[225]	new[223]|giv[224]|new[225]	_	_
25-23	4263-4270	studies	abstract[223]|abstract[224]|abstract[225]	new[223]|giv[224]|new[225]	_	_
25-24	4271-4272	’	abstract[223]|abstract[224]|abstract[225]	new[223]|giv[224]|new[225]	_	_
25-25	4273-4281	findings	abstract[223]|abstract[225]	new[223]|new[225]	_	_
25-26	4282-4288	cannot	_	_	_	_
25-27	4289-4297	indicate	_	_	_	_
25-28	4298-4307	causality	abstract	new	_	_
25-29	4308-4309	.	_	_	_	_

#Text=There is a lack of research into the relationship between the MD and bone fracture risk that clarifies causation or confounding factors .
26-1	4310-4315	There	_	_	_	_
26-2	4316-4318	is	_	_	_	_
26-3	4319-4320	a	abstract[227]	new[227]	_	_
26-4	4321-4325	lack	abstract[227]	new[227]	_	_
26-5	4326-4328	of	abstract[227]	new[227]	_	_
26-6	4329-4337	research	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-7	4338-4342	into	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-8	4343-4346	the	abstract[227]|abstract[228]|abstract[229]	new[227]|new[228]|giv[229]	_	_
26-9	4347-4359	relationship	abstract[227]|abstract[228]|abstract[229]	new[227]|new[228]|giv[229]	_	_
26-10	4360-4367	between	abstract[227]|abstract[228]|abstract[229]	new[227]|new[228]|giv[229]	_	_
26-11	4368-4371	the	abstract[227]|abstract[228]|abstract[229]|abstract[230]	new[227]|new[228]|giv[229]|giv[230]	_	_
26-12	4372-4374	MD	abstract[227]|abstract[228]|abstract[229]|abstract[230]	new[227]|new[228]|giv[229]|giv[230]	_	_
26-13	4375-4378	and	abstract[227]|abstract[228]|abstract[229]	new[227]|new[228]|giv[229]	_	_
26-14	4379-4383	bone	abstract[227]|abstract[228]|abstract[229]|object|abstract[233]	new[227]|new[228]|giv[229]|giv|giv[233]	_	_
26-15	4384-4392	fracture	abstract[227]|abstract[228]|abstract[229]|event|abstract[233]	new[227]|new[228]|giv[229]|giv|giv[233]	_	_
26-16	4393-4397	risk	abstract[227]|abstract[228]|abstract[229]|abstract[233]	new[227]|new[228]|giv[229]|giv[233]	_	_
26-17	4398-4402	that	abstract[227]	new[227]	_	_
26-18	4403-4412	clarifies	abstract[227]	new[227]	_	_
26-19	4413-4422	causation	abstract[227]|abstract	new[227]|new	_	_
26-20	4423-4425	or	abstract[227]	new[227]	_	_
26-21	4426-4437	confounding	abstract[227]|abstract[235]	new[227]|giv[235]	_	_
26-22	4438-4445	factors	abstract[227]|abstract[235]	new[227]|giv[235]	_	_
26-23	4446-4447	.	_	_	_	_
